-
Mashup Score: 83Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study - 9 month(s) ago
ASTX727 plus venetoclax is an active fully oral regimen and safe in most older or unfit patients with acute myeloid leukaemia. Our findings should be confirmed in larger multicentric studies.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 73Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study - 10 month(s) ago
ASTX727 plus venetoclax is an active fully oral regimen and safe in most older or unfit patients with acute myeloid leukaemia. Our findings should be confirmed in larger multicentric studies.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia. Alexandre Bazinet, @garciamanero, @fravandi1 @MDAndersonNews #Leukemia https://t.co/AiuF69MPjK @TheLancetHaem #leusm #AML
-
-
Mashup Score: 147Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies - 10 month(s) ago
γδ T cells play an important role in disease control in acute myeloid leukemia (AML) and have become an emerging area of therapeutic interest. These cells represent a minor population of T lymphocytes with intrinsic abilities to recognize antigens in a major histocompatibility complex-independent manner and functionally straddle the innate and adaptive immunity interface. AML shows high expression of phosphoantigens and UL-16 binding proteins that activate the Vδ2 and Vδ1 subtypes of γδ T cells, respectively, leading to γδ T cell-mediated cytotoxicity. Insights from murine models and clinical data in humans show improved overall survival, leukemia-free survival, reduced risk of relapse, enhanced graft-versus-leukemia effect, and decreased graft-versus-host disease in patients with AML who have higher reconstitution of γδ T cells following allogeneic hematopoietic stem cell transplantation. Clinical trials leveraging γδ T cell biology have used unmodified and modified allogeneic cells a
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet-
Gamma delta T cells are a novel immunotherapy for AML. Recent review from our group https://t.co/v8MgGKyeLv We have clinical trials w Aza Ven & gd2T cell activating ICT01 for Newly Dx AML, & allogeneic gd1T cells for R/R #AML https://t.co/66peT9TKvA https://t.co/LGMVN5oyyl #leusm https://t.co/GAnAXazoBU
-
-
Mashup Score: 64Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials - 10 month(s) ago
Leukemia – Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
The response-based dosing of ponatinib in OPTIC substantially improves cardiovascular risk without compromising efficacy in patients with difficult-to-treat CP-CML. Elias Jabbour of @MDAndersonNews #Leukemia @LeukemiaJnl https://t.co/vsLtuwHXVO
-
-
Mashup Score: 77
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
In this Ph1b trial, single agent SQ blinatumomab resulted in a high MRD-negative complete remission rate & an acceptable safety profile in heavily pretreated adults w/ R/R B-ALL Elias Jabbour of @MDAndersonNews #Leukemia @AjHematology https://t.co/tCSrKobcvz #leusm
-
-
Mashup Score: 54
The development of the BCR::ABL1 tyrosine kinase inhibitors (TKIs) has transformed Philadelphia chromosome (Ph)–positive chronic myeloid leukemia (CML…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
Bosutinib review in #CML - Clinical Lymphoma, Myeloma and Leukemia @DrHKantarjian and Elias Jabbour of @MDAndersonNews #Leukemia https://t.co/g9L5VW9Ura #leusm https://t.co/qDUi4lyY67
-
-
Mashup Score: 106
The combination of low-intensity chemotherapy and inotuzumab ozogamicin (INO), with sequential blinatumomab, is highly effective in older adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) and in relapsed or refractory B-cell ALL. Earlier, “dose-dense” administration of blinatumomab could lead to earlier and deeper measurable residual disease (MRD) responses and better outcomes.
Categories: General Medicine News, Hem/OncsTweet-
Dose-dense mini-hyper-CVD, INO and blina achieves NGS MRD negativity in >90% of pts with new dx B-ALL. A clinical trial at @MDAndersonNews is ongoing. @NicholasShortMD Clinical Lymphoma, Myeloma and Leukemia https://t.co/5VYPgVvKuo https://t.co/D5uVT0V4S9
-
-
Mashup Score: 82SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia - 12 month(s) ago
The outcome of Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) has improved significantly following the introduction of the B…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
Updates on the management of Ph-positive #ALL, the role of ASCT, MRD monitoring, and future therapies Clinical Lymphoma, Myeloma and Leukemia https://t.co/fGTmhX8krK @FadiHaddad_MD, Elias Jabbour, @NicholasShortMD, @NitinJainMD, @DrHKantarjian of @MDAndersonNews #Leukemia #leusm
-
-
Mashup Score: 113Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients - 1 year(s) ago
Arsenic trioxide (ATO)-based regimens are standard in acute promyelocytic leukemia (APL). ATO-related nephrotoxicity has not been reported. We reviewed APL patients treated with ATO to identify cas…
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet-
Arsenic trioxide 0.15 mg/kg without capping (15 mg maximum dose cap) may cause renal damage in obese patients with APL @MDAndersonNews @jenweiying @TapKadia @GBorthakur @MusaYilmazMD @fravandi1 Leukemia & Lymphoma https://t.co/iU04O3Y33q
-
-
Mashup Score: 108Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission - 1 year(s) ago
Key Points. Inotuzumab ozogamicin was safe and effective in eradicating MRD in patients with B-cell acute lymphoblastic leukemia in complete remission.The MRD c
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Inotuzumab is safe and effective for the eradication of MRD in patients with B-cell ALL, with a MRD negativity rate of 69%. Elias Jabbour, @FadiHaddad_MD @DrHKantarjian of @MDAndersonNews #Leukemia https://t.co/b3mdxluZ6O @ASH_Hematology #ALL #leusm https://t.co/uFH87FIfGF
-
In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia. Alexandre Bazinet, @garciamanero, @fravandi1 @MDAndersonNews #Leukemia https://t.co/AiuF69MPjK @TheLancetHaem #leusm #AML